542 related articles for article (PubMed ID: 25209360)
21. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
22. Expression of SIRT1, SIRT3 and SIRT6 Genes for Predicting Survival in Triple-Negative and Hormone Receptor-Positive Subtypes of Breast Cancer.
Uzelac B; Krivokuca A; Brankovic-Magic M; Magic Z; Susnjar S; Milovanovic Z; Supic G
Pathol Oncol Res; 2020 Oct; 26(4):2723-2731. PubMed ID: 32681437
[TBL] [Abstract][Full Text] [Related]
23. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
[TBL] [Abstract][Full Text] [Related]
24. The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma.
Levy AG; Zage PE; Akers LJ; Ghisoli ML; Chen Z; Fang W; Kannan S; Graham T; Zeng L; Franklin AR; Huang P; Zweidler-McKay PA
Invest New Drugs; 2012 Feb; 30(1):191-9. PubMed ID: 20890785
[TBL] [Abstract][Full Text] [Related]
25. Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers.
Hatem R; El Botty R; Chateau-Joubert S; Servely JL; Labiod D; de Plater L; Assayag F; Coussy F; Callens C; Vacher S; Reyal F; Cosulich S; Diéras V; Bièche I; Marangoni E
Oncotarget; 2016 Jul; 7(30):48206-48219. PubMed ID: 27374081
[TBL] [Abstract][Full Text] [Related]
26. ROS-mediated activation and mitochondrial translocation of CaMKII contributes to Drp1-dependent mitochondrial fission and apoptosis in triple-negative breast cancer cells by isorhamnetin and chloroquine.
Hu J; Zhang Y; Jiang X; Zhang H; Gao Z; Li Y; Fu R; Li L; Li J; Cui H; Gao N
J Exp Clin Cancer Res; 2019 May; 38(1):225. PubMed ID: 31138329
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
[TBL] [Abstract][Full Text] [Related]
28. Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas.
Karihtala P; Kauppila S; Soini Y; Arja-Jukkola-Vuorinen
BMC Cancer; 2011 Jun; 11():262. PubMed ID: 21693047
[TBL] [Abstract][Full Text] [Related]
29. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
30. Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition.
Lampa M; Arlt H; He T; Ospina B; Reeves J; Zhang B; Murtie J; Deng G; Barberis C; Hoffmann D; Cheng H; Pollard J; Winter C; Richon V; Garcia-Escheverria C; Adrian F; Wiederschain D; Srinivasan L
PLoS One; 2017; 12(9):e0185092. PubMed ID: 28950000
[TBL] [Abstract][Full Text] [Related]
31. Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro.
Nouri Emamzadeh F; Word B; Cotton E; Hawkins A; Littlejohn K; Moore R; Miranda-Carbon G; Orish CN; Lyn-Cook B
Anticancer Res; 2020 Jul; 40(7):3669-3683. PubMed ID: 32620606
[TBL] [Abstract][Full Text] [Related]
32. Tetraarsenic hexoxide enhances generation of mitochondrial ROS to promote pyroptosis by inducing the activation of caspase-3/GSDME in triple-negative breast cancer cells.
An H; Heo JS; Kim P; Lian Z; Lee S; Park J; Hong E; Pang K; Park Y; Ooshima A; Lee J; Son M; Park H; Wu Z; Park KS; Kim SJ; Bae I; Yang KM
Cell Death Dis; 2021 Feb; 12(2):159. PubMed ID: 33558527
[TBL] [Abstract][Full Text] [Related]
33. Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Madden JM; Mueller KL; Bollig-Fischer A; Stemmer P; Mattingly RR; Boerner JL
Breast Cancer Res Treat; 2014 Sep; 147(2):283-93. PubMed ID: 25129346
[TBL] [Abstract][Full Text] [Related]
34. Recent Progress in Triple Negative Breast Cancer Research.
Mouh FZ; Mzibri ME; Slaoui M; Amrani M
Asian Pac J Cancer Prev; 2016; 17(4):1595-608. PubMed ID: 27221827
[TBL] [Abstract][Full Text] [Related]
35. The Molecular Mechanisms behind Advanced Breast Cancer Metabolism: Warburg Effect, OXPHOS, and Calcium.
Mitaishvili E; Feinsod H; David Z; Shpigel J; Fernandez C; Sauane M; de la Parra C
Front Biosci (Landmark Ed); 2024 Mar; 29(3):99. PubMed ID: 38538285
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
You KS; Yi YW; Kwak SJ; Seong YS
Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
[TBL] [Abstract][Full Text] [Related]
37. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells.
Rossi T; Zamponi R; Chirico M; Pisanu ME; Iorio E; Torricelli F; Gugnoni M; Ciarrocchi A; Pistoni M
J Exp Clin Cancer Res; 2023 Jan; 42(1):7. PubMed ID: 36604676
[TBL] [Abstract][Full Text] [Related]
38. Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies.
Damaskos C; Garmpi A; Nikolettos K; Vavourakis M; Diamantis E; Patsouras A; Farmaki P; Nonni A; Dimitroulis D; Mantas D; Antoniou EA; Nikolettos N; Kontzoglou K; Garmpis N
Anticancer Res; 2019 Oct; 39(10):5285-5296. PubMed ID: 31570423
[TBL] [Abstract][Full Text] [Related]
39. Aurora-A/ERK1/2/mTOR axis promotes tumor progression in triple-negative breast cancer and dual-targeting Aurora-A/mTOR shows synthetic lethality.
Zhang W; Xia D; Li Z; Zhou T; Chen T; Wu Z; Zhou W; Li Z; Li L; Xu J
Cell Death Dis; 2019 Aug; 10(8):606. PubMed ID: 31406104
[TBL] [Abstract][Full Text] [Related]
40. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
